Veracyte Inc stock (US92347M1009): Nasdaq diagnostics name steadies after recent gains

Veracyte shares on Nasdaq were little changed on 06/01/2026 after a strong run in May, keeping the molecular diagnostics group in focus for U.S. healthcare investors.

Veracyte, listed on Nasdaq in the United States under the ticker VCYT, saw its share price stabilize on 06/01/2026 after a notable advance in May that kept the precision diagnostics specialist firmly on the radar of U.S. healthcare investors. The stock most recently changed hands around the mid-40 USD range in late May trading, with Robinhood quoting USD 46.44 per share and a market capitalization of about USD 3.7 billion as of 05/31/2026, according to Robinhood as of 05/31/2026. Activity in Veracyte shares continues to center on expectations for demand in genomic tests used in oncology and other disease areas, while investors track liquidity and price levels on the U.S. home market.

The stock traded near USD 46.44 on 05/31/2026 on Nasdaq, supported by recent interest in molecular diagnostics, according to Robinhood as of 05/31/2026. For German investors following the name via off-exchange platforms, Veracyte is also available on venues such as Tradegate in euros, though liquidity remains concentrated on the U.S. listing, which anchors price discovery and reflects the companys primary shareholder base in the United States.

As of: 01.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Veracyte Inc
• Sector/industry: Genomic diagnostics and precision medicine
• Headquarters/country: South San Francisco, United States
• Core markets: United States with growing presence in Europe and other international markets
• Key revenue drivers: Molecular diagnostic tests and genomic classifiers in oncology and other diseases
• Home exchange/listing venue: Nasdaq (VCYT)
• Trading currency: USD

Veracyte Inc: core business model

Veracyte focuses on developing and commercializing genomic and molecular diagnostic tests that aim to improve clinical decision-making in oncology and other diseases, generating revenue primarily from test volumes and associated diagnostic services provided to physicians and healthcare systems.

What banks and research houses say about Veracyte Inc

No verified analyst coverage was identified at the time of publication.

Conclusion

Veracyte stock on Nasdaq held on to prior gains on 06/01/2026 after a strong May performance, leaving the U.S. diagnostics group trading around the mid-40 USD level last quoted at USD 46.44 as of 05/31/2026. With no fresh analyst notes identified at the time of publication, market attention is likely to remain on how demand for genomic testing, reimbursement trends and broader U.S. healthcare sector moves shape Veracytes trading pattern in the weeks ahead.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.